$1.86 Billion is the total value of Consonance Capital Management LP's 29 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 20.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCRX | Sell | PACIRA PHARMACEUTICALS INC | $179,502,000 | +49.2% | 3,652,134 | -2.7% | 9.66% | +24.5% |
| RTRX | Buy | RETROPHIN INC | $112,454,000 | +7.3% | 3,914,182 | +1.8% | 6.06% | -10.4% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $110,270,000 | +71.9% | 862,295 | +52.1% | 5.94% | +43.5% |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $105,613,000 | -14.5% | 2,303,455 | +10.3% | 5.69% | -28.7% |
| VNDA | Sell | VANDA PHARMACEUTICALS INC | $101,984,000 | +16.2% | 4,443,759 | -3.6% | 5.49% | -3.0% |
| SPPI | Sell | SPECTRUM PHARMACEUTICALS INC | $97,942,000 | -32.9% | 5,829,878 | -16.3% | 5.27% | -44.0% |
| NVRO | Buy | NEVRO CORP | $82,441,000 | +9.5% | 1,446,333 | +53.4% | 4.44% | -8.6% |
| KPTI | Buy | KARYOPHARM THERAPEUTICS INC | $82,205,000 | +1.5% | 4,827,078 | +1.3% | 4.43% | -15.3% |
| AMRN | AMARIN CORP PLCspons adr new | $80,840,000 | +426.5% | 4,968,663 | 0.0% | 4.35% | +339.7% | |
| NUVA | Sell | NUVASIVE INC | $77,334,000 | +34.9% | 1,089,523 | -0.9% | 4.16% | +12.7% |
| MYGN | New | MYRIAD GENETICS INC | $75,731,000 | – | 1,646,330 | +100.0% | 4.08% | – |
| PACB | Buy | PACIFIC BIOSCIENCES CALIF IN | $73,105,000 | +63.7% | 13,512,958 | +7.5% | 3.94% | +36.7% |
| LMNX | Buy | LUMINEX CORP DEL | $71,805,000 | +68.8% | 2,369,008 | +64.5% | 3.87% | +40.9% |
| URGN | Buy | UROGEN PHARMA LTD | $71,573,000 | -3.3% | 1,515,422 | +1.9% | 3.85% | -19.3% |
| CORT | Buy | CORCEPT THERAPEUTICS INC | $70,645,000 | -2.9% | 5,038,874 | +8.9% | 3.80% | -18.9% |
| EXEL | Buy | EXELIXIS INC | $68,737,000 | -0.5% | 3,879,050 | +20.9% | 3.70% | -16.9% |
| VCEL | Buy | VERICEL CORP | $58,979,000 | +68.5% | 4,168,092 | +15.5% | 3.18% | +40.7% |
| STML | STEMLINE THERAPEUTICS INC | $45,603,000 | +3.4% | 2,747,198 | 0.0% | 2.46% | -13.7% | |
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $39,750,000 | +31.8% | 2,449,184 | +4.7% | 2.14% | +10.0% |
| QURE | UNIQURE NV | $38,030,000 | -3.7% | 1,045,065 | 0.0% | 2.05% | -19.6% | |
| VSTM | Sell | VERASTEM INC | $37,368,000 | -24.2% | 5,154,224 | -28.1% | 2.01% | -36.7% |
| SVRA | Buy | SAVARA INC | $34,526,000 | +12.5% | 3,093,690 | +14.1% | 1.86% | -6.1% |
| ADMA | Buy | ADMA BIOLOGICS INC | $28,189,000 | +47.1% | 4,539,295 | +6.8% | 1.52% | +22.8% |
| RARX | RA PHARMACEUTICALS INC | $26,317,000 | +81.8% | 1,454,761 | 0.0% | 1.42% | +51.7% | |
| TBPH | New | THERAVANCE BIOPHARMA INC | $23,911,000 | – | 731,909 | +100.0% | 1.29% | – |
| CPRX | CATALYST PHARMACEUTICALS INC | $22,849,000 | +21.2% | 6,044,719 | 0.0% | 1.23% | +1.1% | |
| SESN | SESEN BIO INC | $16,175,000 | +10.3% | 7,523,296 | 0.0% | 0.87% | -7.9% | |
| INVA | New | INNOVIVA INC | $15,281,000 | – | 1,002,675 | +100.0% | 0.82% | – |
| ANIP | ANI PHARMACEUTICALS INC | $8,082,000 | -15.4% | 142,943 | 0.0% | 0.44% | -29.4% | |
| FLXN | Exit | FLEXION THERAPEUTICS INC | $0 | – | -217,392 | -100.0% | -0.36% | – |
| CSII | Exit | CARDIOVASCULAR SYS INC DEL | $0 | – | -305,235 | -100.0% | -0.64% | – |
| GWPH | Exit | GW PHARMACEUTICALS PLCads | $0 | – | -364,300 | -100.0% | -3.28% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.